web analytics
6.4 C
Munich
Wednesday, October 5, 2022

Stemtech Corp (OTCMKTS: STEK) Globe Net Wireless Reverse Merger Promo Breaking Out Northbound

Stemtech Corp (OTCMKTS: STEK) has been rocketing up the charts in recent trading initially rocketing up in July from $5 to $9, dropping back down to $4 and rocketing up northbound again recently surpassing $9.90 per share. STEK is a major league promotion from some heavy hitters that could easily go much higher but when the bottom falls out, it could drop fast. The promoters on STEK are top of the game suggesting it could easily continue for a while and see much higher levels. In July STEK reported in a press release they were notified by OTC Markets of a foreign stock promotion which we were unaware of, and provided Stemtech Corporation with a copy of an article from a UK web site called “World Finance”, which emphatically predicted share price appreciation in the Stem Cell arena in general, and our Company in particular. This promotion apparently based their material solely upon the past history of one of our Directors from publicly available material. Neither the Board nor our sole IR specialist, Winthorp Capital, have any knowledge of or involvement with said unknown third-party promotion; and would have remained ignorant of it but for the notice received from OTC Markets.

Stemtech went public on August 19, 2021 via a reverse merger into Globe Net Wireless Corp. The merger is accounted for as a reverse acquisition and recapitalization in accordance with the Financial Accounting Standards Board (ASC 805, Business Combinations). STEK and its Subsidiaries was incorporated in the State of Nevada, USA on September 4, 2009 under the name Globe Net Wireless Corp. with ticker symbol “GNTW”. While STEK changed its corporate name to Stemtech Corp. in the state of Nevada, the Company is currently awaiting FINRA approval of said name change at the time of this filing.  On August 4, Stemtech made a presentation at the Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming OTCQB Venture Virtual Investor Conference to be held on August 4th. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Stemtech Corp (OTCMKTS: STEK) is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes its products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. The Company’s mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Companies subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, DermaStem®, DermaStem Lift, OraStem® (Oral Health Care), and D-Fuze™. 

Stemtech has pioneered and patented a whole new category of dietary supplements. Stemtech’s advanced Stem Cell Nutrition formulations are one-of-a-kind natural products designed to help support the three most important aspects of stem cell physiology: 1) Releasing more stem cells; 2) their circulation in the blood; and 3) Migration into tissues, where they can perform their daily function of renewal and rejuvenation for optimal health. We actually harness the incredible power of adult stem cells. How does this work? Adult stem cells are released from your bone marrow into the bloodstream, they then Circulate in the bloodstream and flow to the tissues most in need. As they arrive, the adult stem cells migrate into the tissues, reproduce and become new, healthy cells of those tissues. This process takes place every single day, even without tissue damage, as part of the natural renewal system of the body. It is important to understand that Stemtech’s products do not contain stem cells. They are composed of natural botanicals and other ingredients that have been clinically documented to support the performance of your own adult stem cells. 

The Company is now reengaging over 200,000 former distributors since a recent cash infusion. STEK has engaged experienced marketing and social media professionals to initiate new marketing strategies which are expected to bring increased activity. Moreover, it is now better positioned to absorb significant new clientele as the company has directed significant cash towards our inventory, and we now have enough inventory on hand to fulfill over $3 million dollars’ worth of new orders, an inventory level we have not had since going into bankruptcy in 2017. Management conservatively believes that given the cash on hand and working expenditures as describe above, it can reinvigorate sales to be more consistent with the company’s previous revenue historically, as it was recognized 4 times in the Inc 5000 Magazine’s list of fastest growing companies. 

To Find out the inside Scoop on STEK Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

 

STEK

Below this IBP level, STEK has its “DTC” (Direct To Consumer) network marketing Distribution model. This integrative model allows us an immediate global presence and ability to operate in multiple countries on any continent. The Company is uniquely positioned in this post pandemic economy beset by supply chain issues, as this method requires no up-front or required buy-in of inventory, with monthly shipments available for known recurring sales. This platform has us now operating at the intersection of the ecommerce economy, social economy and gig economy. 

While sales of product obviously create the cash flow, the Company’s real business model is not just “sales”, but lateral penetration. We do this through our IBPs – “Independent Business Partner” Sales Forces, and we invest much energy in growing our IBPs. Post public listing and funding, Stemtech is projecting the addition of 30,000 new independent business partner reps over the next 12 to 24 months, adding to the existing IBPs. With an enhanced compensation plan, IBPs will be even more incentivized to build their network, attracting additional industry leaders. IBPs are a testimonial to our product and business model, lowering our customer acquisition costs. 

In July Stemtech adopted a suite of sales enablement software solutions, developed by Verb Technology Company, Inc. (Nasdaq: VERB), including verbCRM, VERB’s white-labelled interactive video-based customer relationship management application, and verbLIVE, VERB’s interactive livestream eCommerce and shoppable video and webinar application, for use in direct selling and customer and prospect communications by its network of Independent Business Partners (IBPs). 

Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. Its patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. Its products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). Stemtech has a history of innovation, was the first to market in the category of stem cell nutrition and was recognized four separate times by Inc. 5000 Fastest-Growing Companies list. Stemtech’s primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income-earning potential to IBPs. 

 For More on STEK Subscribe Right Now!

Currently trading at a $409,455,081 million market valuation, STEK OS is 44,945,673 and the float is just 6,483,034 shares. STEK is an SEC filer and fully reporting OTCQB. The Company has just over $500,000 in the treasury and $5.1 million in assets vs. 9.5 million in liabilities. STEK is starting to book some solid revenues reporting $1,156,308 in sales for the 3 months ended March 31, 2022 up from $1,075,761 for the same period last year. STEK has been rocketing up the charts in recent trading initially rocketing up in July from $5 to $9, dropping back down to $4 and rocketing up northbound again recently surpassing $9.90 per share. STEK is a major leaque promotion from some heavy hitters that could easily go much higher but when the bottom falls out, it could drop fast. The promoters on STEK are top of the game suggesting it could easily continue for a while and see much higher levels. Recently STEK has been averaging between $1 and $3 million per day in dollar volume. We will be updating on STEK when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in STEK either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.